Novartis Issues Debt Offering to Help Fund $12B Acquisition of Avidity Biosciences

Dow Jones

Mar 17

By Kelly Cloonan

Novartis is issuing debt offerings to help fund its $12 billion acquisition of Avidity Biosciences.

The Swiss pharmaceutical company plans to use the proceeds from the sale of the notes for general corporate purposes outside of Switzerland, including to repay outstanding borrowings under the bridge loan it entered last month to finance the Avidity acquisition, according to a filing with the Securities and Exchange Commission.

Novartis didn't disclose the size of the debt offering. The offering includes eight tranches, with notes due in 2029, 2031, 2033, 2036, 2046 and 2056 and floating rate notes due in 2029 and 2031.

The company's acquisition of Avidity closed in February, adding to a series of smaller acquisitions and licensing agreements that have allowed Novartis to fill its drug pipeline. Avidity brings two experimental drugs for neuromuscular diseases.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

March 16, 2026 13:29 ET (17:29 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2620498618"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620498618\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620498618?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-17 01:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620498618","market":"fut","top_or_hot":-1,"title":"Novartis Issues Debt Offering to Help Fund $12B Acquisition of Avidity Biosciences","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Novartis is issuing debt offerings to help fund its $12 billion acquisition of <a href=\"https://laohu8.com/S/RNA\">Avidity Biosciences</a>. \n</p>\n<p>\n  The Swiss pharmaceutical company plans to use the proceeds from the sale of the notes for general corporate purposes outside of Switzerland, including to repay outstanding borrowings under the bridge loan it entered last month to finance the Avidity acquisition, according to a filing with the Securities and Exchange Commission. \n</p>\n<p>\n  Novartis didn't disclose the size of the debt offering. The offering includes eight tranches, with notes due in 2029, 2031, 2033, 2036, 2046 and 2056 and floating rate notes due in 2029 and 2031. \n</p>\n<p>\n  The company's acquisition of Avidity closed in February, adding to a series of smaller acquisitions and licensing agreements that have allowed Novartis to fill its drug pipeline. Avidity brings two experimental drugs for neuromuscular diseases. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 16, 2026 13:29 ET (17:29 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis Issues Debt Offering to Help Fund $12B Acquisition of Avidity Biosciences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis Issues Debt Offering to Help Fund $12B Acquisition of Avidity Biosciences\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-17 01:29</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Novartis is issuing debt offerings to help fund its $12 billion acquisition of <a href=\"https://laohu8.com/S/RNA\">Avidity Biosciences</a>. \n</p>\n<p>\n  The Swiss pharmaceutical company plans to use the proceeds from the sale of the notes for general corporate purposes outside of Switzerland, including to repay outstanding borrowings under the bridge loan it entered last month to finance the Avidity acquisition, according to a filing with the Securities and Exchange Commission. \n</p>\n<p>\n  Novartis didn't disclose the size of the debt offering. The offering includes eight tranches, with notes due in 2029, 2031, 2033, 2036, 2046 and 2056 and floating rate notes due in 2029 and 2031. \n</p>\n<p>\n  The company's acquisition of Avidity closed in February, adding to a series of smaller acquisitions and licensing agreements that have allowed Novartis to fill its drug pipeline. Avidity brings two experimental drugs for neuromuscular diseases. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 16, 2026 13:29 ET (17:29 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B2B36J28.USD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2620498618","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620498618","pubTimestamp":1773682140,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Novartis is issuing debt offerings to help fund its $12 billion acquisition of Avidity Biosciences.The Swiss pharmaceutical company plans to use the proceeds from the sale of the notes for general corporate purposes outside of Switzerland, including to repay outstanding borrowings under the bridge loan it entered last month to finance the Avidity acquisition, according to a filing with the Securities and Exchange Commission.Novartis didn't disclose the size of the debt offering. The offering includes eight tranches, with notes due in 2029, 2031, 2033, 2036, 2046 and 2056 and floating rate notes due in 2029 and 2031.The company's acquisition of Avidity closed in February, adding to a series of smaller acquisitions and licensing agreements that have allowed Novartis to fill its drug pipeline. Avidity brings two experimental drugs for neuromuscular diseases.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4588":"碎股","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4007":"制药","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","BK4532":"文艺复兴科技持仓","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4139":"生物科技","NVS":"诺华","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4505":"高瓴资本持仓","BK4578":"CAR-T","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","RNA":"Atrium Therapeutics"},"translate_title":"诺华发行债务为120B美元收购Avidity Biosciences提供资金","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVS":0.9,"RNA":1.5},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Novartis is issuing debt offerings to help fund its $12 billion acquisition of Avidity Biosciences. \n\n\n  The Swiss pharmaceutical company plans to use the proceeds from the sale of the notes for general corporate purposes outside of Switzerland, including to repay outstanding borrowings under the bridge loan it entered last month to finance the Avidity acquisition, according to a filing with the Securities and Exchange Commission. \n\n\n  Novartis didn't disclose the size of the debt offering. The offering includes eight tranches, with notes due in 2029, 2031, 2033, 2036, 2046 and 2056 and floating rate notes due in 2029 and 2031. \n\n\n  The company's acquisition of Avidity closed in February, adding to a series of smaller acquisitions and licensing agreements that have allowed Novartis to fill its drug pipeline. Avidity brings two experimental drugs for neuromuscular diseases. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 16, 2026 13:29 ET (17:29 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}